You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • FRI0184 Cost-effectiveness and budget impact of certolizumab pegol against the current mix of anti-tnf treatments in an outcomes-based risk-sharing scheme in finland

Alerts

Article menu
Download PDFPDF
Poster Presentation
Rheumatoid arthritis - anti-TNF therapy
FRI0184 Cost-effectiveness and budget impact of certolizumab pegol against the current mix of anti-tnf treatments in an outcomes-based risk-sharing scheme in finland
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address